Comparative Pharmacology
Head-to-head clinical analysis: GALLIUM CITRATE GA 67 versus SODIUM IODIDE I 123.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GALLIUM CITRATE GA 67 versus SODIUM IODIDE I 123.
GALLIUM CITRATE GA 67 vs SODIUM IODIDE I 123
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gallium citrate Ga 67 is a radiopharmaceutical that localizes in tumors and inflammatory lesions. The mechanism is not fully understood but may involve binding to transferrin and uptake via transferrin receptors, as well as accumulation in lysosomes of macrophages and tumor cells.
Sodium iodide I 123 is a radioactive isotope that emits gamma radiation. Following oral or intravenous administration, it is rapidly absorbed and selectively concentrated in the thyroid gland via the sodium-iodide symporter (NIS). The emitted gamma rays allow for imaging of thyroid tissue and detection of abnormal uptake patterns.
2-5 mCi (74-185 MBq) intravenously once; repeat imaging may require an additional 2-5 mCi at 48-72 hours.
Oral: 400-800 μCi (14.8-29.6 MBq) for thyroid uptake studies; 150-300 μCi (5.6-11.1 MBq) for thyroid scan. Administer orally as a single dose.
None Documented
None Documented
Terminal elimination half-life: approximately 25 days (range 6-72 days) in soft tissues; reflects slow clearance from binding sites (e.g., transferrin, lactoferrin).
13.2 hours (physical T1/2); effective T1/2 ~13 hours in euthyroid; prolonged in hypothyroidism.
Renal: approximately 25% within first 24 hours; fecal: approximately 10% within 48 hours; retained in tissues (bone, liver, spleen) with slow release over weeks.
Primarily renal (90%) as iodide; small amount feces (<5%) and negligible biliary.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical